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Background: Host cell microRNAs (miRNAs) have been shown to regulate the expression of both cellular and viral
RNAs, in particular impacting both Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). To investigate
the role of miRNAs in regulating replication of the simian immunodeficiency virus (SIV) in macrophage lineage cells,
we used primary macrophages to study targeting of SIV RNA by miRNAs. We examined whether specific host
miRNAs directly target SIV RNA early in infection and might be induced via type I interferon pathways.
Results: miRNA target prediction programs identified miRNA binding sites within SIV RNA. Predicted binding sites
for miRs-29a, -29b, -9 and -146a were identified in the SIV Nef/U3 and R regions, and all four miRNAs decreased
virus production and viral RNA expression in primary macrophages. To determine whether levels of these miRNAs
were affected by SIV infection, IFNβ or TNFα treatments, miRNA RT-qPCR assays measured miRNA levels after
infection or treatment of macrophages. SIV RNA levels as well as virus production was downregulated by direct
targeting of the SIV Nef/U3 and R regions by four miRNAs. miRs-29a, -29b, -9 and -146a were induced in primary
macrophages after SIV infection. Each of these miRNAs was regulated by innate immune signaling through TNFα
and/or the type I IFN, IFNβ.
Conclusions: The effects on miRNAs caused by HIV/SIV infection are illustrated by changes in their cellular
expression throughout the course of disease, and in different patient populations. Our data demonstrate that levels
of primary transcripts and mature miRs-29a, -29b, -9 and -146a are modulated by SIV infection. We show that the SIV
3′ UTR contains functional miRNA response elements (MREs) for all four miRNAs. Notably, these miRNAs regulate virus
production and viral RNA levels in macrophages, the primary cells infected in the CNS that drive inflammation leading
to HIV-associated neurocognitive disorders. This report may aid in identification miRNAs that target viral RNAs and HIV/
SIV specifically, as well as in identification of miRNAs that may be targets of new therapies to treat HIV.
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Approximately 34 million people worldwide are cur-
rently infected with HIV according to the World
Health Organization (http://www.who.int/features/qa/
71/en/index.html). As a result of the development of
Highly Active Antiretroviral Therapy (HAART),
infected individuals are living longer, healthier lives
than just two decades ago. Despite this success,* Correspondence: jclements@jhmi.edu
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reproduction in any medium, provided the orpatients living with HIV often suffer from complica-
tions associated with long-term infection such as car-
diac and neurological disorders, in addition to side
effects from antiretroviral drugs [1,2]. Along with
HAART treatment, recently there has been research
targeted at HIV eradication focused on therapeutic
vaccine development [3], purging the latent reservoirs
that harbor virus [4], and reducing the expression of
the CCR5 co-receptors [5], cell-surface proteins, used
by HIV for entry into cells. To this end, a better un-
derstanding of HIV-host interactions is needed.
The type I IFN response is a major host defense
against virus infection [6,7]. HIV infection initiates a cas-
cade of cytokine induction and innate immune signaling.
In our SIV macaque model of HIV central nervous. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fluid, basal ganglia and parietal cortex shows distinct dif-
ferences in innate immune responses between the per-
iphery and the CNS. This is exhibited by the presence of
viral RNA accompanied by induction of IFNβ and IFNβ-
inducible MxA in the CNS as early as 4 days after infec-
tion [8]. CD4+ T cells are the main cells in the periphery
that become infected, in contrast to the central nervous
system (CNS), where CD14+ macrophages are the pre-
dominant productively infected cells [9-15]. Previous
studies have demonstrated that circulating cells from the
monocyte/macrophage lineage become infected and traf-
fic to the brain where they induce cytokine signaling and
also infect other macrophage lineage cells and astrocytes
[6,16]. Many cytokines, including IFNβ, are produced by
virus-infected or virus-exposed cells. Soluble IFNβ pro-
duced by infected cells binds to uninfected cells to signal
through the type I IFN receptor, activating over 100
interferon-stimulated genes as well as antiviral proteins
such as MxA [17]. Thus, the signal is amplified and a
robust antiviral response is activated to prevent the
spread of infection. Cellular restriction factors are an-
other host defense against HIV infection. These include,
but are not limited to, TRIM5α [18,19], APOBEC3G
[20,21], SAMHD1 [22,23] and miRNAs [24,25].
miRNAs are small regulatory molecules that fine-tune
levels of target mRNAs in the cell through binding to
MREs in target mRNAs. Binding results in post-
transcriptional repression caused by target mRNA deg-
radation, translational inhibition and/or sequestration
[26]. Each miRNA may have hundreds of predicted tar-
get mRNAs, resulting in regulation of expression for
close to 60% of human mRNAs [27]. miRNAs regulate
human physiology at the level of cell cycle and differen-
tiation [28] and innate immune signaling and antiviral
mechanisms [29-32], as well as yet to be identified genes
and pathways. Their actions extend into roles in patho-
genesis of several viruses including Hepatitis C [30,33],
influenza [34,35], herpes viruses [36,37] and HIV.
miRNAs influence several stages of HIV-1 infection.
Humans infected with HIV-1 have alterations in miRNA
profiles [38] with differences in distinct miRNA popula-
tions in patients with varying levels of CD4+ T cell
count/plasma HIV RNA copies [39] and elite suppres-
sors [40-43], indicating involvement of miRNAs in re-
sponse to virus infection. HIV modulates levels of
several miRNAs at various time points after infection
[44,45] and is also regulated by miRNAs in multiple
ways [46]. Specific miRNAs target cytokines important
in the immune response [47], as well as transcription
factors, such as Cyclin T1 [48], which are necessary for
transcription of viral genes. Some or all of miRNAs
miRs-28, -125b, -150, -223 and -382 are reportedly in-
volved in differential susceptibility of active and restingCD4+ T cells [49,50] and monocytes and macrophages
[51,52] to HIV infection. Multiple reports suggest direct
targeting of HIV-1 by host miRNAs [24,44,53-56].
Hariharan et al., used in silico analysis to identify target
sites for host miRNAs in HIV-1 vpr (miR-149), vif (miR-
324-5p), vpu (miR-378) and nef-LTR (miRs-29a and -29b)
[53]. A follow-up study by the same group demonstrated
miR-29a regulation of Nef expression and HIV-1 replica-
tion, and suggested that this was due to miRNA targeting
the HIV-1 Nef transcript [24]. The miR-29 family was also
reported to inhibit replication of HIV-1, demonstrating
that the RNA-induced Silencing Complex (RISC) protein,
Ago2, and P body protein, RCK/p54, directly interact with
viral RNA in a miR-29a-dependent manner [54]. Nathans,
et al. also showed that miR-29a binds the same MRE in
HIV-1 as predicted by Hariharan et al. [53], and this site is
conserved across HIV-1 subsets [54]. Sun et al. identified
MREs for several miRNAs within HIV-1 and reported
downregulation of miRs-21, 155, -29a, -29b and -29c, and
an upregulation of miR-223 in response to HIV-1 infection
in CD4+ T cells [55]. This group also reported only weak
repression of a pNL4-3-Luc reporter by miRs-29a, -29b
and -223, hypothesizing that this was due to a hairpin in
this region of HIV-1 RNA sequence that interfered with
RISC/miRNA binding [55]. In contrast to Sun et al.,
Schopman et al. found induction of miR-29a in several cell
types in response to HIV-1 infection [44]. This difference
may be due to time after infection when miRNA levels
were measured or the specific cells that were used for the
studies. Finally, Houzet et al. used anti-HIV-1 miR-326 as
an example that sequence complementarity between a
miRNA and its target mRNA correlates with inhibited ex-
pression of that target mRNA [56]. Together, these reports
demonstrate modulation in levels of at least 13 human
miRNAs during HIV-1 infection in various cell types. Two
of these miRNAs (miRs-29a and -29b) have been validated
by more than one study to have an effect on, or to directly
target HIV-1 RNA transcripts [24,53-55].
We have developed a rapid and consistent SIV ma-
caque model of HIV/AIDS and CNS disease in order to
study the cellular and viral molecular events and patho-
genesis during acute, asymptomatic and AIDS stage of
disease [6-9,57]. We have shown both in vivo and
in vitro that TNFα and IFNβ are induced during acute
infection in SIV-infected macaques [7,8], and both cyto-
kines regulate several miRNAs [30,32,58]. We demon-
strate here that TNFα and IFNβ induce specific miRNAs
at very early time points after SIV infection. SIV infec-
tion and cytokine stimulation of primary macrophages
were used to dissect the mechanisms of miRNA induc-
tion, innate immune signaling and control of virus infec-
tion. We evaluated these miRNAs in regard to their
effects on virus replication and mRNA levels, ability to
target viral RNA sequences and modulation by innate
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the four miRNAs, miR-29a, -29b, -9 and -146a, are in-
duced in macrophages during innate immune signaling
and target the viral RNA, reducing virus replication and
virus production.
Results
Predicted miRNA recognition elements (MREs) in SIV
3′ UTR
miRNA target prediction programs [59,60] were used to
identify potential miRNA binding sites within the 3′ un-
translated region (UTR) of SIV 17E-Fr (Figure 1,
Additional file 1: Table S1). Many miRNAs were identi-
fied that have predicted MREs in the SIV RNA 3′ UTR,
and we focus here on miRs-29a, -29b, -9 and -146a,
(Figure 1A and B). All four miRNAs contain promoter
binding sites for transcription factors induced during in-
nate immune signaling. miRs-29a and -29b are predicted
to contain two ISRE (STAT1/STAT2 heterodimer in-
duced by type I IFN signaling) GAS (STAT1 homodimer
activated by IFNγ signaling) binding sites in the pro-
moter [61] and are induced in response to IFNα/β and
IFNγ. The miR-9 promoter contains an NF-κB binding
site and is induced by TNFα in an NF-κB-dependent
manner [58]. The miR-146a promoter is regulated by























Figure 1 Predicted miRNA binding sites within the 3′ UTR of SIV. miRa
29a, -29b, -9 and -146a. (A) A graphic representation of the SIV 3′ UTR with
generated from predictions.innate immune signaling. In addition, the ability of
miRs-29a and -29b to target HIV-1 transcripts has been
supported by multiple studies [24,53-55]. The transcrip-
tional activation of these miRNAs, in addition to the
predicted binding sites in the SIV RNA sequence, sug-
gests miRs-29a, -29b, -9 and -146a may be induced
during the innate immune response and inhibit viral
replication.
Effects of miRs-29a, -29b, -9 and -146a on SIV production
in primary macrophages
To determine if the miRNAs with predicted binding
sites in the UTR of SIV have an effect on virus produc-
tion, macaque macrophages were transfected or not with
each of the miRNAs and infected with SIV twenty-four
hours after transfection. Levels of virus released from
cells were measured at 24, 48 and 72 hours post-
infection (p.i.). At 24 hours p.i., miR-29a, -29b, -9
and -146a reduced virus production from ~250 pg/ml of
p27 protein to below the limit of detection (~60 pg/ml)
(Figure 2). There was a statistically significant decrease
in virus production at 48 hours post-infection by miRs-
29a and -29b. miR-9 continued to reduce p27 levels to
below the limit of detection and miR-146a reduced p27
levels to below the limit of detection in cells from one









UCU---A-CCACGAu -5’  miR-29a
AGAGCCUGGGUGUUC -3’  SIV R 10009-10056
:
U--A----CCACGAu -5’  miR-29a/b
ACUUGGCCGGUGCUg -3’  SIV R 10058-10090
AUU-GGU-UUCu -5’  miR-9
U-ACCCAGAAGa -3’  SIV Nef/U3 9744-9770
-U-CAAGA--Gu -5’  miR-146a
GAGGUUCUAGCa -3’  SIV Nef/U3 9678-9711
--G----U-CAAGAGu -5’  miR-146a
CCCUGGGAGGUUCUCu -3’  SIV R 9985-10025
nda and RNAhybrid prediction programs identified MREs for miRs-
predicted MREs. (B) Alignment of MREs within the SIV 3′ UTR



















































































** *** * ** *** **
Figure 2 Four miRNAs reduce levels of SIV virus production. Primary macaque macrophages were transfected with 100 nM miRNA mimics,
then infected with SIV (MOI 0.05) 24 hours after transfection. Supernatants were collected at 24, 48 and 72 hours post-infection and analyzed for
virus production. Data shown is an average of at least 3 experiments for each miRNA at each time point. (x) indicates levels at or below the limit
of detection, ~60 pg/ml (gray line). Results reported are p27 pg/ml values averaged from at least 3 separate experiments. All statistics reported
are the result of a paired, two-sided t test performed on p27 values of time-point matched samples with untransfected controls. * = p < 0.05,
** = p < 0.01, *** = p < 0.001.
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(Figure 2). A statistically significant decrease in virus
production was maintained by all four miRNAs through
72 hours post-infection (Figure 2).miRNA-mediated reduction of full-length and spliced SIV
RNA
To investigate whether these miRNAs exert anti-SIV
effects through transcript degradation or translation in-
hibition, total cellular RNA was isolated from the same
cells used in Figure 2. Full-length and multiply-spliced
(tat/rev) viral RNA levels were measured by RT-qPCR.
All four miRNAs significantly decreased the levels of full-
length (Figure 3A) as well as multiply-spliced (Figure 3B)
SIV RNA. Full length and spliced RNA levels were most
significantly reduced at 24 hours after infection when
viral RNA abundance is lowest (Figure 3A and B, left
panels). Experiments were also performed using 25 nM
of miR-29b and the same reduction in SIV RNA levels
was observed using this 4-fold lower miRNA concentra-
tion (data not shown).
We hypothesized that miRNA-specific antisense oligo-
nucleotides (antagonists) that decrease the levels of
available miRNAs would lead to an increase in viral
RNA. Antagonists were transfected into macaque mac-
rophages, and cell lysates were collected at 48 hours
post-infection. We found that miRNA antagonists for
miRs-29a, -29b and -146a significantly increased levels
of SIV RNA when compared to SIV-infected untreated
cells (Figure 3C). Inhibition of miR-9 did not increase
viral RNA levels. This was presumably due to the fact
that this miRNA is approximately 1000-fold less abun-
dant than miRs-29a and -146a (data not shown), andinhibition by low copy number miRNAs may be ineffi-
cient [63,64].
Effects of miRs-29a, -29b, -9 and -146a on expression of a
luciferase reporter
After identifying predicted miRNA binding sites in the
SIV 3' UTR and considering that all four miRNAs re-
duce levels of SIV RNAs and inhibit virus production, a
luciferase assay was performed to examine the effects of
the four miRNAs on expression of luciferase from a
plasmid containing the predicted sites. Transfection of
293 T cells was done with a luciferase reporter plasmid
alone, or a plasmid with genomic regions containing the
SIV 3′ UTR. Luciferase expression was measured in the
absence and presence of miRs-29a, -29b, -9 and -146a.
Addition of each miRNA resulted in a dose-dependent
inhibition of reporter gene expression (Figure 4A).
Transfection with two different scrambled mimics had
no effect on expression of the reporter gene (Figure 4A).
Direct targeting of MREs in the SIV 3′ UTR
To determine whether the predicted SIV 3′ UTR MREs
were bound by the predicted targeting miRNAs, we
transfected into HeLa cells biotinylated 50-nucleotide
RNA oligonucleotide molecules (oligos) that corresponded
to wild-type (WT) or mutated (mt) MRE seed-binding
SIV U3-R regions (Figure 4B). We calculated the differ-
ence in the percent of each miRNA precipitated by WT
and mt oligos. Cells were lysed, and the biotinylated oligo-
nucleotides were selected with strepavidin. Recovered
miRNA was quantitated by RT-qPCR. The two predicted
SIV 3′ UTR seed binding sites for miR-29 family members
were included in two oligos corresponding to nucleotides































































































































































































Figure 3 Four miRNAs reduce levels of full length and multiply spliced viral RNAs. Primary macaque macrophages were transfected with
100 nM of either miRNA mimics or antagonists, then infected with SIV (MOI 0.05) 24 hours after transfection. Cell lysates were collected at 24, 48
and 72 hours post-infection for miRNA experiments and 48 hours for miRNA antagonist experiments. Levels of full length (A, C) and spliced (B)
RNA was measured by RT-qPCR. Values are expressed as fold change over SIV-only controls. Results are reported as percent of SIV-only control
using the ΔΔCq method.
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the oligo corresponding to nts 9740–9789 of the SIV
RNA. The two predicted sites for miR-146a were included
in two oligos corresponding to nts 9680–9729 and 10000–
10049 of the SIV RNA (Figure 4B). miRs-29a and -29b
bound to the site contained within nts 10063–10112 of
the SIV genome, however, neither miR-29a nor miR-29b
bound to the predicted site within nts 10039–10070
(Figure 4C). miR-9 bound to its predicted site contained
within nts 9740–9789 (Figure 4C). miR-146a bound to the
predicted site contained within nts 9680–9729, but did
not bind to the predicted site contained within nts 10000–
10049 (Figure 4C). These results demonstrate that there
are functional binding sites for miRs-29a, -29b, -9 and
-146a within the SIV 3′ UTR.
Upregulation of mature anti-SIV miRNAs during SIV
infection of primary macrophages
To examine whether SIV infection affects the levels of
miRs-29a, -29b, -9 and -146a, each of these miRNAs
was measured in primary macaque macrophages after
SIV infection and compared with miRNA levels in unin-
fected time-point controls. Levels of all 4 miRNAsincreased during infection (Figure 5). Primary macro-
phages were infected with SIV, and RNA was isolated at
2, 4, 8, 12, 24 and 48 hours post-infection. miR-29a
and -29b levels increased together at 12 hours and by
50% and 60%, respectively, at the 48-hour time point
(Figure 5A and B). Levels of miR-9 increased approxi-
mately 50-85% 4 hours after infection in three out of
four animals (Figure 5C). There was also an increase in
miR-146a levels at 12 and 24 hours after infection, with
the largest average increase being 50% at 24 hours
(Figure 5D). These data demonstrate an induction of
mature miRNA levels during early stages of SIV infec-
tion and suggest that an increase in the levels of these
miRNAs may contribute to the decrease in SIV replica-
tion and viral RNA levels that we have shown here.
IFNβ-mediated upregulation of precursor and mature
anti-SIV mRNAs
The increase in levels of miRs-29a, -29b, -9 and −146
(Figure 5) in response to SIV infection is unlikely to be
caused directly by the virus, since the only viral proteins
in the cells at this time are from the virion. IFNβ has


















































































































































Figure 4 miRs-29a, -29b, -9 and -146a reduce expression of a luciferase reporter and target predicted binding sites in the 3′ UTR of
SIV. (A) SIV nef/U3-R was cloned into psiCHECK2 plasmid (Promega). 293T cells were co-transfection with 50 nM or 100 nM of each miRNA or
scrambled mimic and 100 ng of either psiCHECK+SIV or psiCHECK alone. Control samples were transfected with either psiCHECK or psiCHECK+SIV, and
no miRNA mimics. Cells were harvested 24 hours after transfection. Data shown is an average of four experiments and represents miRNA effect
on luciferase expression for psiCHECK+SIV over psiCHECK only. (B) WT and mutant biotin-labeled oligos corresponding to SIV RNA sequences
containing predicted miRNA binding sites. WT oligo is show on top and mutant on bottom. Boxed bases on WT oligo denote miRNA seed
binding site in SIV sequence. Mutant oligo highlighted bases denote the change in seed-binding region. Annotation is based on SIV sequence
AY033146. (C) 100 pmol of individual WT or mt oligos were transfected into HeLa cells and lysates collected 24 hours after transfection. Oligos
were pulled down using Streptavidin beads and assayed for binding to endogenous cellular miRNAs using Taqman RT-qPCR. Percent input was
calculated for each sample (see methods) and data presented as (% input mt )/(% input WT) with % of input of WT set to 100%. In each
experiment, the value of the oligo which pulled down the highest percentage of individual endogenous miRNA was set to 100% and binding
by other oligos was compared to this value. Data shown is an average of 4 experiments. Statistics represent the comparison of percent of
miRNA bound to WT oligo compared to percent of miRNA pulled down by corresponding mt oligo and are reported as a two-tailed t test
assuming unequal variance.
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and -29b [61]. We examined the effects of IFNβ treat-
ment of cells on the expression levels of all four
miRNAs. Human macrophages were used so that both
the mature and pri-miRNAs could be measured (pri-
miRNA assays have not been developed for macaque se-
quence). Macrophages were treated with IFNβ, and RNAwas extracted at 4, 8, 12 and 24 hours after treatment.
IFNβ caused a modest but consistent increase in the
levels of miRs-29a and -29b at early time points, with no
discernable difference observed for miRs-9 and -146a
(Figure 6A-D). miR-29a was increased significantly at
eight hours by 25% and miR-29b was increased similarly



















Hours after SIV infection




































Figure 5 SIV infection increases levels of mature miR- 29a (A), -29b (B), -9 (C) and -146a (D). Macaque macrophages were infected with
SIV (MOI 0.05). Cells were harvested at 2, 4, 8, 12, 24 and 48 hours after infection and RNA was isolated. Taqman miRNA RT-qPCR assays were
used to measure levels of mature miRNAs. Results were normalized to U6, then to uninfected samples for the individual time points (ΔΔCq
method). Values are expressed as fold induction of miRNAs over uninfected controls using the ΔΔCq method and data shown is an average of
at least 3 experiments.
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This data shows that IFNβ induction early in infection
leads to an increase in levels of miR-29a and -29b in
primary human macrophages. IFNβ treatment produ-
ces similar results in primary macaque macrophages
(Additional file 2: Figure S1A-D).
The increase in levels of mature miRNAs can be due
to a decrease in miRNA turnover, an increase in
transcription of precursor miRNAs (pri-miRNAs), or an
increase in mature miRNA processing. To address at
what level these miRNAs were being increased, pri-
miRNA levels were measured in primary human macro-
phages at 2, 4, 8, 12 and 24 hours after IFNβ treatment
(Figure 6E-H). Expression of pri-miRs-29a and -29b was
significantly increased ~2-fold at 2, 4 and 8 hours after
IFNβ treatment (Figure 6E and F). Coordinated regula-
tion of these two miRNAs was expected, as they are part
of the same transcript. Expression of miR-146a was
increased 44% at 8 hours after treatment (Figure 6H).
Transcription of miR-9 was significantly decreased at all
time points (Figure 6G), explaining the lack of induction
of the mature miRNA by IFNβ. An increase in the
pri-miRNA indicates IFNβ stimulation caused an
upregulation of the transcriptional activation of the three
miRNA.The canonical response to IFNβ was confirmed by
measuring the levels of the interferon-stimulated gene,
mxa. Both SIV infection and IFNβ stimulation signifi-
cantly increased mxa expression (Additional file 3:
Figure S2A,B), and IFNβ also reduced viral RNA levels
(Additional file 3: Figure S2C). These results demon-
strate canonical signaling of pathways downstream of
IFNβ in our primary macrophage system.
TNFα signaling drives expression of IFNβ and anti-SIV
miRNAs
In primary macrophages, IFNβ stimulation modulates
levels of pri- and mature miRs-29a and 29b, and pri-miR
-146a (Figure 6A-H). Like IFNβ, TNFα is induced during
the acute phase of SIV infection as part of the innate
immune response [8], and TNFα has been shown to
increase expression of IFNβ and interferon-stimulated
genes [65]. TNFα stimulation of primary macrophages
resulted in an increase in the IFNβ-stimulated gene,
mxa (Additional file 4: Figure S3), demonstrating regula-
tion of this pathway by TNFα. To test the effect of
TNFα stimulation on miRNA levels, primary macro-
phages were treated or not with TNFα and cells
harvested at 2, 4, 8, 12 and 24 hours after treatment.
TNFα stimulation resulted in an increase in miR-29a






























































































Figure 6 IFNβ increases levels of mature miRNAs and primary miRNA transcripts in human macrophages. Human macrophages were
treated with 100 U/ml IFNβ and cells were harvested at 4, 8, 12 and 24 hours after treatment and RNA isolated. (A-D) Taqman miRNA RT-qPCR
assays were used to measure levels of mature miRNAs. (E-H) Taqman pri-miRNA RT-qPCR assays were used to measure levels of primary miRNA
transcripts. Results were normalized to U6. Values are expressed as fold induction of miRNAs over uninfected controls using the ΔΔCq method
and data shown is an average of at least 3 experiments.
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http://www.retrovirology.com/content/10/1/95and -29b levels by an average of 30% and 35%, respect-
ively, at 12 hours (Figure 7A and B). miR-9 levels in-
creased significantly at 2 and 24 hours after treatment
by an average of 40% and 90%, respectively (Figure 7C).
Levels of miR-146a increased maximally by an averageof 55% at 24 hours (Figure 7D). Macaque macropha-
ges responded similarly to stimulation with TNFα
(Additional file 5: Figure S4A-D).
TNFα stimulation also induced transcriptional expres-
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Figure 7 TNFα increases levels of mature miRNAs and primary miRNA transcripts in human macrophages. Human macrophages were
treated with 20 ng/ml TNFα. Cells were harvested at 2, 4, 8, 12 and 24 hours after treatment and RNA isolated. (A-D) Taqman miRNA RT-qPCR
assays were used to measure levels of mature miRNAs. (E-H) Taqman pri-miRNA RT-qPCR assays were used to measure levels of primary miRNA
transcripts. Results were normalized to U6. Values are expressed as fold induction of miRNAs over uninfected controls using the ΔΔCq method
and data shown is an average of at least 3 experiments.
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http://www.retrovirology.com/content/10/1/95expression increased by ~45% 2 hours after treatment,
with a maximum increase of 55% 4 hours after treat-
ment (Figure 7E). Similarly, pri-miR-29b expression in-
creased maximally 2 hours after treatment by 55% and
remained elevated by ~40% 4 hours (Figure 7F). Therewas a dramatic 10-fold increase of pri-miR-9 2 hours
after treatment with TNFα. This increase was main-
tained at 5-fold 4 hours after treatment, and 2-fold
through the 12 hour time point (Figure 7G). pri-miR
-146a expression increased by 2-fold 2 and 4 hours after
Sisk et al. Retrovirology 2013, 10:95 Page 10 of 15
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through the 12-hour time point (Figure 7H).
Discussion
The identification of miRNAs as regulators of gene
expression has dramatically changed the understanding
of post-transcriptional regulation of cellular and viral
genes. A number of viruses encode miRNAs in their
genome that regulated cellular genes required for repli-
cation [66]. We have previously shown that miRNAs in
plasma of SIV-infected macaques provide a signature of
infection and progression to CNS disease, demonstrating
that SIV infection affects miRNA expression in vivo [67].
In this study, we demonstrate for the first time that four
miRNAs directly bind to the U3 region of the SIV RNA.
Further, all four miRNAs, miR-29a, -29b, -9 and -146a,
controlled SIV virus production and replication by de-
creasing SIV full length and spliced tat/rev RNAs in
infected primary macrophages. In addition we provide
evidence that these four miRNAs are transcriptionally
regulated by the innate immune response, specifically,
TNFα and type I IFN. We have shown previously that
virus replication in macrophages increases both of these
cytokines and thus, it appears that these miRNAs are
part of the innate antiviral immune response to SIV.
The protein products of spliced rev and tat transcripts
are critical early in infection for progression to later
stage and productive infection. The 3′ UTR of SIV con-
tains MREs for all four miRNAs, miRs-29a, -29b, -9 and
-146a. All SIV RNAs share the same 3′ UTR sequence
and therefore, these four miRNAs have the capability to
target all full-length and spliced viral transcripts for
degradation. In order to have a significant impact on
virus infection and the propagation of virus, one would
hypothesize that miRNAs would target the early
multiply-spliced genes, preventing the progression of
virus replication to the productive stage. In addition, we
hypothesized that the levels of the miRNAs would be
high in the cell or would increase within hours following
infection in a cell or be upregulated in response to early
cytokines in bystander cells, preventing virus spread to
other cells. Levels of the anti-SIV miRNAs studied here
increased as early as 4 hours post-infection, and miRs-
29a, -29b and -146a were significantly induced by 24
and 48 hours after infection, respectively. From these
results, we see that viral infection in macrophages
upregulates miRNAs that regulate the virus.
It has been shown for virus infections, including HIV
and SIV, that infection of cells, particularly macrophages,
leads to the induction of innate immune responses, type
I IFN and TNFα [8,17]. To determine whether the
increased levels of the four miRNAs that reduce virus
infection were induced by the cellular response to infec-
tion, we used INFβ and TNFα to examine the inductionof mature as well as pri-miRNAs. INFβ and/or TNFα,
two cytokines that are made in response to SIV infection
in macrophages increased the four miRNAs. INFβ in-
creased miRs-29a and -29b as early as 2 hours after
treatment. TNFα, in contrast increased levels of miRs-
29a, -29b and -146a at 12 hours suggesting that its effect
was due to stimulation of type I IFN. TNFα may have a
direct effect on miR-9 since the miRNA was significantly
increased at 2 hours and appears not to be modulated
through the type I IFN response. Overall, levels of the
mature form of these miRNAs increased approximately
50% over control.
While these increases were modest, we found them
consistently, and it is important to remember that viral
infection drastically alters the pre-existing miRNA-target
network in many ways. Upon infection, host miRNAs
that may have multiple host targets are provided with
many copies of a new, viral target. The abundance of
cellular transcript targets may also be modulated. Since
the number of targets of a specific miRNA and the affin-
ity of the targeting miRNA for each target together in-
fluence the magnitude of regulation along with the
abundance of the miRNA itself, large fold changes or in-
deed any modulation of targeting miRNA are not neces-
sarily prerequisites for regulation of an evolutionarily
novel target. Further investigations of the entire network
are needed to establish the necessary stoichiometries
for effective regulation. We would also note that this
miRNA/target network is even more complicated in vivo,
as levels of the characterized miRNAs may be altered in
cell types other than macrophages. These miRNAs may
traffic between cells [68] and may be recycled within a
given cell [69], thereby enhancing their effects.
A second important finding is that innate immune re-
sponses induced these miRNAs at the transcriptional
level. During this early time after infection, SIV spliced
RNA encoding Rev and Tat are produced, and this is
likely the time when miRNA levels are most efficiently
targeting viral transcripts to reduce virus replication. Ex-
pression of each miRNA transcript is controlled by spe-
cific transcription factors. The promoters of miRs-29a,
-29, -9 and -146a all contain one or more binding sites
for NF-κB [58,70,71], a transcription factor induced by
innate immune signaling. These reports show that miRs-9
and -146a are induced by TNFα and induction of miR-
146a is dependent on the three NF-κB binding sites found
in its promoter. In cancer cells, TLR signaling and NF-κB
activation were shown to suppress expression of miRs-29a
and -29b [70], but the promoter for these two miRNAs
contains binding sites for several other transcription
factors related to innate immune signaling.
While miRs-29a, -29b, -9 and -146a did not evolve to
target SIV, they reduced virus production via direct
interaction with specific sequences in the 3′ UTR of SIV
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late virus infection directly as well as indirectly. For
example, miR-29a has been shown to target IFNγ [72].
A report by Chiang et al., demonstrates direct binding of
Cyclin T1 by miR-29b and [73], a transcription factor
necessary for replication of HIV-1. miR-9 is induced by
TLR signaling and NF-κB activation and regulates ex-
pression of the NF-κB p50 subunit [58,74]. miRNA-146a
is a negative regulator of innate immunity and overex-
pression results in downregulation of type I IFN in
PBMCs due to targets within IRAK1 and TRAF6
[71,75-78]. miR-146a was also reported to target and in-
hibit expression of CXCR4 [79], a cell surface receptor
used by HIV-1 and certain strains of SIV. miRNAs are
differentially expressed at various times in different tis-
sues. Furthermore, individual miRNAs may have differ-
ent factors controlling maturation as well as rates of
degradation. More investigation is needed to elucidate
the connections between IFNβ/TNFα signaling and our
observed modulation of transcription of these miRNAs.
What is becoming clear is that this miRNA response
reflects another downstream antiviral innate immune
effector.
Several lines of evidence suggest that miRNAs may be
useful as therapeutic inhibitors of HIV-1 infection.
These data include: 1) a relationship between differences
in miRNA profiles and cell type susceptibility to HIV-1
infection [49-52]; 2) dysregulation of miRNAs during
HIV-1 infection [39] and 3) direct miRNA targeting of
HIV-1 RNA sequences [54-56]. These reports show the
potential for miRNAs to be given therapeutically as
potent inhibitors of HIV-1 infection. The main obstacle
is delivery of these molecules to a desired tissue or cell
population. Several groups have reported nanoparticle
delivery of antiretrovirals and siRNAs in HIV-infected
cells in vitro as well as in mouse models of neuroAIDS
[80]. These methods appear promising for delivery to
specific cell and tissue types, as well as only to cells that
are infected. Obad et al. demonstrated using short LNA
antagomiRs to target entire miRNA families [81], and
this strategy could be used to inhibit miRNAs that are
overexpressed during infection and increase either virus
infection or contribute to pathogenesis. We show here
that miRs-29a, -29b, -9 and -146a are four anti-SIV
miRNAs that have the potential to be used as thera-
peutic agents against SIV infection.
Conclusion
To our knowledge, this study is the first report linking
viral as well as innate immune modulation of miRNAs
with direct targeting of viral RNAs and inhibition of
virus production. The significant role of miRNAs in the
pathogenesis of HIV is underscored by the abundance
of reports demonstrating miRNA effects on diseaseprogression as well as effects of virus on miRNA expres-
sion. The early induction of miRs-29a, -29b, -9 and
-146a caused by SIV and the significant inhibition of
virus production very early in infection suggests poten-
tial for using these as well as other miRNAs for treat-
ment of HIV in addition to other infectious diseases.
Our macaque model of SIV provides an ideal model for
testing delivery and efficacy of treatment with miRNAs.
Future strategies include using anti-SIV miRNAs or
miRNAs that target transcription factors and other pro-
teins necessary for replication of HIV and SIV. Targeted
delivery to infected cells or individual cell types may re-




Animal studies were approved by the Johns Hopkins
University Institutional Animal Care and Use Committee
(Protocol # PR09M296) and conducted in accordance
with the Weatherall Report, the Guide for the Care and
Use of Laboratory Animals, and the USDA Animal
Welfare Act.
miRNA prediction programs
The SIV 3′ UTR sequence, consisting of nef/U3-R (SIV/
17E-Fr nucleotides 9462–10155), was analyzed for
miRNA binding sites. Results from miRanda [59] and
RNAhybrid [60] were compiled to identify predicted
miRNA binding sites within the SIV 3′ UTR. The mini-
mum free energy cutoff for miRNA consideration was
set at −20 kcal/mol, and the free energy of each miRNA/
target site interaction is in Additional file 1: Table S1.
Luciferase assays
The SIV 3′ UTR (nef/U3-R, SIV 17E-Fr nts 9458–10160)
was cloned into the psiCHECK-2 vector (Promega) 3′ of a
Renilla luciferase reporter gene. 293 T cells were plated at
80,000 per well of a 24-well plate. Cells were approxi-
mately 90% confluent 24 hours later for co-transfection of
individual miRNA mimics and either psiCHECK-2 plas-
mid plus SIV insert or psiCHECK-2 plasmid with no in-
sert. Controls were transfected with either psiCHECK-2 or
psi-CHECK-SIV 3′ UTR, but no miRNA mimics. Cells
were harvested 24 hours later and assayed for luciferase
expression using the Renilla Luciferase Assay System
(Promega) and measured on (Fluoroskan Ascent FL,
Thermo Scientific). The raw luciferase value of each sam-
ple was normalized to total protein for that sample to con-
trol for well-to-well differences in cell number. Firefly
luciferase was not used for normalization as all four
miRNAs reduced levels of this control reporter. Several in-
dividual plasmids were co-transfected to use as transfec-
tion controls but were not able to be included because
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placing the miRNA mimics with scrambled mimics
(scrambled #1 Ambion mirVana miRNA mimic Negative




Macaque macrophages were obtained from rhesus and
pigtail macaque donors. Human macrophages were
obtained from leukopacks from anonymous donors of
the Johns Hopkins Hospital HATS donation center.
Whole blood was diluted with HBSS, loaded onto a
Ficoll gradient and centrifuged for 30 minutes at
2000 rpm. Plasma was removed and PBMCs were re-
moved from the interface of plasma and Ficoll. Cells
were washed in HBSS and pelleted (1500 rpm for 10 mi-
nutes) twice prior to red blood cell lysis (15 ml of
150 mM NH4CL, 10 mM KHCO3 and 1 mM EDTA for
15 minutes at 37°C). 35 ml of HBSS was added, and
PBMCs were centrifuged to remove red blood cell lysis
buffer. Cells from individual donors were plated separ-
ately (donor samples were not pooled) at 4×106 cells per
well in 12-well plates or 10×106 cells per well in 6-well
plates and cultured for 7 days in medium containing M-
CSF and 20% autologous serum. One half of the total
volume of medium was replaced on day 3. On day 7,
cells were washed 3 times with PBS to remove non-
adherent cells. The medium was replaced the same as
above, only with 10% serum. Infection and treatments
were all performed on day 8 after plating.
miRNA transfection and SIV infection
Rhesus or pigtail macaque macrophages were approxi-
mately 90% confluent on day eight post-plating when
transfected with 100 nM of individual miRNAs or miRNA
antagonists (Qiagen) for 6 hours using Lipofectamine
2000 (Invitrogen/Life Technologies) diluted in OptiMEM
Reduced Serum Medium (Life Technologies) as per
manufacturer’s instructions. Mock transfections included
Lipofectamine 2000 and OptiMEM, but no miRNA
mimic.. Twenty-four hours later, cells were infected with
macrophage tropic SIV 17E-Fr [GenBank:AY033146.1] at
an MOI of 0.05 for six hours. Following infection, cells
were washed 3 times with PBS, and fresh medium was
added. Supernatants and cells were collected at 24, 48 and
72 hours post infection to measure virus production and
viral RNA levels, respectively. All results shown are the
average of at least three separate experiments.
IFNβ and TNFα treatment
Day 8 pigtail macaque macrophages were approximately
90% confluent when treated with either 100 U/ml IFNβ(PBL Interferon Source) or 20 ng/ml TNFα (R&D Sys-
tems, human 210-TA-010, macaque 1070-RM-025). Total
RNA was isolated from control and treated samples at 2,
4, 8, 12 and 24 hours post-infection. All results shown are
the average of at least three separate experiments.
miRNA isolation
All RNA isolation was performed using the mirVana
miRNA Isolation Kit (Ambion). Cells were harvested in
600 μl Lysis/Binding Buffer and eluted with 100 μl
water. Samples were treated with 2 μl TURBO DNase
(Ambion) for 45 minutes at 37°C. Samples were re-
extracted using the mirVana miRNA Isolation Kit
cleanup protocol and eluted with 100 μl water.
Analysis of SIV p27
200 μl of supernatant was used for p27 assays (Zepto-
metrix). The assay was performed following an overnight
incubation of samples in lysis buffer at 37°C. p27 levels
were determined based on the manufacturer’s provided
standard. All results shown are the average of at least
three separate experiments.
RT-qPCR
Results are reported as fold change using the ΔΔCq
method. All statistics reported represent 2-tailed t tests
assuming unequal variance, performed on ΔΔCq values
of time-point matched samples with untreated/unin-
fected controls. All results shown are the average of at
least three separate experiments.
SIV transcripts
250 ng of RNA was used for reverse transcription cDNA
synthesis (Superscript III, Invitrogen/Life Technologies).
RT-qPCR was performed as described previously using
primers and probes specific for SIV gag and tat/rev tran-
scripts [82]. Quantification cycle (Cq) values were nor-
malized to an average of the GAPDH and18S Cq values
as well as to time-point controls.
Taqman RT-qPCR – mature miRNAs
10 ng of total RNA was used for reverse transcription
cDNA synthesis using the Taqman microRNA Reverse
Transcription Kit (Applied Biosystems) and Taqman as-
says for individual miRNAs. 5 μl of cDNA was used for
RT-qPCR with individual miRNA Taqman assays. Cq
values were normalized to a U6 internal control as well
as to time-point controls.
Taqman RT-qPCR – pri-miRNAs
100–250 ng of total RNA was used for reverse transcrip-
tion cDNA synthesis using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). 4 μl of
cDNA was used for RT-qPCR with Taqman precursor
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were normalized to a U6 internal control as well as to
time-point controls.RNA immunoprecipitation
HeLa cells were plated using 200,000 cells per well of a
6-well plate and 24 hours later were approximately 90%
confluent when transfected with Lipofectamine 2000
(Invitrogen) with 400 pmol of a biotinylated 50-nucleotide
WT or mutant RNA oligo corresponding to the predicted
regions of binding for individual miRNAs (see Figure 5A).
Twenty-four hours after transfection cells were fixed in
0.5% formaldehyde for 15 minutes at room temperature.
Cross-linking was stopped by 5 minute incubation at
room temperature in 0.25 M glycine, pH 7. Fixed cells
were lysed in modified RIPA buffer [82] for 30 minutes at
4°C. Lysed cells were centrifuged for 10 minutes at
14,000 rpm at 4°C. 5% of total sample volume was taken
for input. Lysates were incubated for 30 minutes at room
temperature with 100 μl of streptavidin beads (Dynabeads
MyOne Streptavidin C1, Life Technologies) to pull down
endogenous miRNAs bound to the biotinylated oligos.
Beads were washed 3 times with 500 μl RIPA Buffer. After
reverse cross-linking (5 minutes at 65°C in 100 μl of 95%
formamide, 10 mM EDTA pH 8.0), 500 μl of mirVana
Binding/Lysis Buffer was added to the supernatant and
RNA was extracted using the mirVana miRNA Isolation
Kit (Ambion). 10 μl of total RNA was used in Taqman
miRNA-specific qPCR primer/probe assays to detect spe-
cific miRNAs bound to individual oligos containing pre-
dicted miRNA binding sites. Percent of pull down by each





For mRNA and miRNA comparisons that only consisted
of two groups (uninfected/untreated versus infected/
treated) a paired, two-sided t test was performed on the
well-specific observations (relative to the control average)
at each time point. Each miRNA was statistically evalu-
ated as the duplicate- or triplicate-averaged difference
from C(q) U6 or 18S and GAPDH relative to control.
Statistical significance, p-value <0.05, indicates an effect
of intervention. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.Additional files
Additional file 1: Table S1. Binding energies for each miRNA site
within the SIV LTR sequence, predicted by miRanda and RNAhybrid. The
minimum binding energy threshold was set to −20 kcal/mol.Additional file 2: Figure S1. A-D. IFNβ increases levels of mature
miRNAs in macaque macrophages. Macaque macrophages were treated
with 100 U/ml IFNβ. Cells were harvested at 4, 8, 12 and 24 hours after
treatment and RNA was isolated. Taqman miRNA RT-qPCR assays were
used to measure levels of mature miRNAs. Results were normalized to
U6. Values are expressed as fold induction of miRNAs over untreated
controls using the ΔΔCq method and data shown is an average of at
least 3 experiments.
Additional file 3: Figure S2. SIV infection and IFNβ stimulation
increases mxa levels. IFNβ decreases SIV RNA levels. Macaque
macrophages were infected with SIV (A), infected with SIV and treated
with IFNβ (C) and primary human macrophages were treated with IFNβ
(B). RT-qPCR using sequence-specific primers and probe for mxa was
used to measure mxa and SIV RNA levels. Results were normalized to 18S.
Values are expressed as fold induction of mxa over uninfected/untreated
controls using the ΔΔCq method and data shown is an average of at
least 3 experiments.
Additional file 4: Figure S3. TNFα induced expression of mxa in
primary macaque and human macrophages. Macaque (A) and human
(B) macrophages were treated with 20 ng/ml macaque or human TNFα.
RNA was isolated at 2, 4, 8, 12 and 24 hours after treatment. Sequence-
specific primers and probe for mxa were used for RT-qPCR. Results were
normalized to 18S. Values are expressed as fold induction of mxa over
untreated controls using the ΔΔCq method and data shown is an
average of at least 3 experiments.
Additional file 5: Figure S4. A-D. TNFα increased levels of mature
miRNAs in macaque macrophages. Macaque macrophages were treated
with 20 ng/ml TNFα. Cells were harvested at 4, 8, 12 and 24 hours after
treatment and RNA isolated. Taqman miRNA RT-qPCR assays were used
to measure levels of mature miRNAs. Results were normalized to U6.
Values are expressed as fold induction of miRNAs over untreated controls
using the ΔΔCq method and data shown is an average of at least 3
experiments.
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